Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.41 |
| ▸ | TNF | P01375 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.34 |
| ▸ | BRAF | P15056 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29447086 | 1.00 | L3MBTL1 (0.46) | L3MBTL1KDM4EIP6K1ALDH1A1HPGD | |
| SCHEMBL22324042 | 0.94 | L3MBTL1 (0.46) | L3MBTL1KDM4EIP6K1ALDH1A1HPGD | |
| SCHEMBL28703844 | 0.89 | HDAC6 (0.45) | L3MBTL1KDM4EIP6K1ALDH1A1HPGD | |
| SCHEMBL15680577 | 0.86 | L3MBTL1 (0.50) | L3MBTL1KDM4EIP6K1ALDH1A1HPGD | |
| SCHEMBL12351357 | 0.82 | L3MBTL1 (0.47) | L3MBTL1KDM4EIP6K1ALDH1A1HPGD | |
| SCHEMBL22323913 | 0.78 | HDAC6 (0.48) | L3MBTL1KDM4EIP6K1ALDH1A1HPGD | |
| SCHEMBL4782862 | 0.78 | HDAC6 (0.51) | L3MBTL1KDM4EIP6K1ALDH1A1HPGD | |
| SCHEMBL29377697 | 0.78 | HDAC6 (0.48) | L3MBTL1KDM4EIP6K1ALDH1A1HPGD | |
| SCHEMBL31559881 | 0.77 | L3MBTL1 (0.46) | L3MBTL1KDM4EIP6K1ALDH1A1HPGD | |
| SCHEMBL24037759 | 0.76 | ALDH1A1 (0.49) | L3MBTL1KDM4EIP6K1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12509460-B2 | Methods and compositions for modulating splicing | SKYHAWK THERAPEUTICS, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-20230020922-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-01-19 | — | — | US | disclosed |
| CN-114126613-A | Methods and compositions for modulating splicing | 斯基霍克疗法公司 | 2022-03-01 | — | — | CN | disclosed |
| EP-3920926-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | Skyhawk Therapeutics, Inc. (US) | 2021-12-15 | — | — | EP | disclosed |
| WO-2020163541-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. (US) | 2020-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230020922-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SNRPA1 | L3MBTL1 176/4885KDM4E 2530/4885IP6K1 1492/4885 |
| US-12509460-B2 | Methods and compositions for modulating splicing | SF3B1, RTCB, RBM17 | L3MBTL1 384/4885KDM4E 2036/4885IP6K1 2574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.